تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
8.33 US$
+0.32 US$ · +4.00%
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
الإغلاق السابق
8.33 US$
+0.32 US$ · +4.00%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
نطاق اليوم
السعر الحالي 8.33 US$
نطاق 52 أسبوعًا
السعر الحالي 8.33 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
32
مرتفع السعر
المشاعر
44
مختلط
المخاطر
56
مخاطر أعلى من المعتاد
الزخم
54
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
نطاق اليوم
السعر الحالي 8.33 US$
نطاق 52 أسبوعًا
السعر الحالي 8.33 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
8.33 US$
ارتفاع محتمل بنسبة 0.00%| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 15 نوفمبر 2018 | 1:20 | — | — |
ساري 15 نوفمبر 2018
1:20
صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Russell 2000 ETFIWM7.64 مليون0.01%78.74 مليار USD0.19%278.94 US$+0.49%
iShares Russell 2000 Growth ETFIWO2.75 مليون0.02%13.92 مليار USD0.24%356.78 US$+0.94%
Vanguard Extended Market ETFVXF2.29 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
Vanguard Russell 2000 ETFVTWO1.33 مليون0.01%18 مليار USD0.06%112.66 US$+0.50%
iShares Micro-Cap ETFIWC919.37 ألف0.07%1.32 مليار USD0.60%183 US$+0.11%
Vanguard Russell 2000 Growth ETFVTWG257.27 ألف0.01%1.7 مليار USD0.06%260.49 US$+0.91%
Global X - Russell 2000 ETFRSSL144.83 ألف0.01%1.42 مليار USD0.08%109.09 US$+0.21%
ProShares Russell 2000 High Income ETFITWO17.78 ألف0.01%184.98 مليون USD0.55%43.06 US$+0.96%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGGlobal X - Russell 2000 ETFRSSLProShares Russell 2000 High Income ETFITWOالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
